Your abstract or session must be submitted under one of the official tracks for the conference:
Note this is to assist with programme planning, track choice has no impact on the selection process.
Abstract and session submissions are now closed, but satellite session submissions will remain open till June 30, 2021.
|
TRACK A: BASIC AND TRANSLATIONAL RESEARCH |
|
Scope for this track includes basic sciences, pre-clinical and product development for TB and other lung health conditions |
|
A1. Immunology |
|
A2. Drug and vaccine development, including for COVID-19 |
|
A3. TB diagnostics, including drug-resistance determination |
|
A4. COVID-19: molecular and immuno diagnostics |
|
TRACK B: CLINICAL AND OPERATIONAL RESEARCH |
|
Scope for this track includes clinical trials, pragmatic trials, operational research on prevention, diagnosis and treatment of TB and other lung health conditions, including post-TB lung disease. Targeted populations may include children or any other age group, vulnerable sub-populations or people living with other co-morbidities. |
|
B1. TB diagnostics |
|
B2. Clinical trials and operational research for new treatments for drug sensitive-TB and drug resistant-TB in adults |
|
B3. Clinical trials and operational research for COPD, pneumonia, asthma and other lung health in adults |
|
B4. Clinical trials and operational research for new treatments for drug sensitive-TB and drug resistant-TB in children |
|
B5. Clinical trials and operational research for COPD, pneumonia, asthma and other lung health in children |
|
B6. Active case finding and contact investigation for TB |
|
B7. Identification and management of TB infection |
|
B8. TB and co-infections: including HIV and diabetes |
|
B9. Lung health (other than TB) and co-morbidities |
|
B10. Tobacco and co-morbidities: including NCDs, TB and HIV |
|
B11. COVID-19: clinical and operational research |
|
TRACK C: POLICIES AND CLINICAL & PROGRAMMATIC IMPLEMENTATION |
|
Scope for this track includes the review and evaluation of global and local policies, clinical practices and programmatic implementation across the spectrum of prevention, diagnosis and treatment of TB and other lung health conditions, including post-TB lung disease; including research on improvement of current policies and practices |
|
C1. TB infection (LTBI) |
|
C2. TB care and treatment in drug sensitive-TB |
|
C3. TB care and treatment in drug resistant-TB |
|
C4. Paediatric TB treatment and care |
|
C5. Paediatric lung disease, excluding TB |
|
C6. Maternal and child health: TB and lung disease |
|
C7. Post-TB lung health |
|
C8. Person-centered care |
|
C9. Access to quality TB care and services |
|
C10. Global and local policies and politics, including funding and accountability |
|
C11. TB laboratory service implementation and operations |
|
C12. TB education and training |
|
C13. Tobacco control and tobacco industry interference |
|
C14. MPOWER for tobacco control |
|
C15. COVID-19: policies and clinical implementation |
|
TRACK D: EPIDEMIOLOGY |
|
Scope for this track includes all aspects of epidemiology relating to TB, lung disease, tobacco control and co-morbidities such as HIV. |
|
D1. TB epidemiology in adults |
|
D2. TB epidemiology in children |
|
D3. Epidemiology of COPD, pneumonia, asthma and other lung health conditions in adults |
|
D4. Epidemiology of COPD, pneumonia, asthma and other lung health conditions in children |
|
D5. Air pollution |
|
D6. Epidemiology of transmission and TB infection |
|
D7. TB infection control |
|
D8. Post-TB lung health |
|
D9. HIV-TB and other HIV-related lung health |
|
D10. Modelling, including modelling of COVID-19: the effect of social controls, preparedness and lessons for other infectious diseases. |
|
D11. Health economics |
|
D12. Tobacco-related epidemiology |
|
D13. E-cigarettes and non-combustible tobacco products |
|
D14. COVID-19 |
|
TRACK E: POLITICS, CIVIL SOCIETY AND HUMAN RIGHTS |
|
Scope includes research on and assessment of social, political, legal and human rights factors, stigma and discrimination influencing prevention, treatment, care and support for persons impacted by lung health issues, as well as communication of these issues to relevant stakeholders. |
|
E1. Civil society, advocacy and community engagement |
|
E2. Key affected populations: behavioural, social, and cultural issues and contexts |
|
E3. Human rights |
|
E4. Ethics |
|
E5. Communication/social media |
|
TRACK F: ZOONOTIC TB |
|
Scope for this track includes studies on the epidemiology, prevention, diagnosis, and treatment challenges posed by zoonotic tuberculosis caused primarily by Mycobacterium bovis; to assist animal and public health agencies in more effectively controlling this disease and collaborating on field and laboratory research. |
|
F1. Basic science and zoonotic diagnostics |
|
F2. Zoonotic treatment |
|
F3. Zoonotic epidemiology |
|
F4. One Health |